Congratulations to HJ SCIENCE-B (Stock Code: 6132.HK) on the Successful IPO on the Main Board of the HKEX!

CR SWCS Team is honoured to serve as the Joint Company Secretary of HJ SCIENCE-B, committed to ensuring governance, compliance, and sustained growth.

COMPANY PROFILE

HJ SCIENCE-B is a clinical-stage biotech company founded in 2017 by a team of industry experts, focusing on autoimmune, metabolic, and oncology diseases. The Company has three core products – HJ787 (a selective TYK2 inhibitor for autoimmune diseases), HJ178 (an oral GLP-1/GIP dual-target agent for type 2 diabetes and obesity), and HJ891 (an oral KRAS G12C inhibitor for non-small cell lung cancer) – all of which are self-developed, small-molecule NMPA Category 1 innovative drugs.

Source: https://www.hj3h.com/